Cappetta Merissa, Murnion Bridin P
Drug Health Services, Sydney Local Health District, Camperdown, NSW, Australia.
Drug and Alcohol Services, Central Coast Local Health District, Wyong Hospital, Hamlyn Terrace, NSW, Australia.
Australas Psychiatry. 2019 Jun;27(3):284-287. doi: 10.1177/1039856218822748. Epub 2019 Jan 17.
To describe the baseline characteristics, treatment and retention in patients electively admitted for gamma-hydroxybutyrate (GHB) withdrawal management.
All patients admitted between July 2010 to June 2016 who used GHB two or more times per week with a minimum duration of 3 months were identified and data extracted by file review.
Twelve cases satisfied the inclusion criteria, of whom 50% were female; 75% were using GHB daily, with an average daily amount of 16 ml. Average duration of use was 60 months. All subjects were using amphetamine type stimulants and nicotine. Psychiatric comorbidity and unintentional overdose were common; 50% completed treatment. Medications used included diazepam and neuroleptic. Two patients completed withdrawal with no medications. No subject using greater than 90 ml GHB in the preceding week completed treatment. Pattern of GHB use did not predict medication requirements during withdrawal management.
There were low numbers attending for elective treatment for GHB use. Heavier GHB use predicted poor treatment retention. Polysubstance use and psychiatric co-morbidities need consideration in treatment planning.
描述因γ-羟基丁酸（GHB）戒断管理而择期入院患者的基线特征、治疗情况及治疗依从性。
确定2010年7月至2016年6月期间所有每周使用GHB两次或以上且使用时间至少3个月的入院患者，并通过查阅病历提取数据。
12例患者符合纳入标准，其中50%为女性；75%的患者每日使用GHB，平均每日用量为16毫升。平均使用时长为60个月。所有受试者均同时使用苯丙胺类兴奋剂和尼古丁。精神疾病共病和意外过量用药情况较为常见；50%的患者完成了治疗。使用的药物包括地西泮和抗精神病药物。两名患者未使用药物完成了戒断。前一周使用GHB超过90毫升的受试者无一完成治疗。GHB的使用模式并不能预测戒断管理期间的药物需求。
因使用GHB而接受择期治疗的患者人数较少。大量使用GHB预示着治疗依从性较差。在制定治疗计划时需要考虑多药合用及精神疾病共病情况。
